Investors considering a purchase of Harrow Inc (Symbol: HROW) stock, but tentative about paying the going market price of $35.48/share, might benefit from considering selling puts among the ...

Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% ...

Harrow, Inc. shares have dropped 45% since spring 2023, but the launch of Iheezo and Vevye suggest a potential rebound. Iheezo, an ocular anesthetic, has a substantial market opportunity and is ...